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Diabetes can result in loss of enteric neurons and subsequent gastrointestinal complications. The mecha-
nism of enteric neuronal loss in diabetes is not known. We examined the effects of hyperglycemia on enteric 
neuronal survival and the effects of glial cell line–derived neurotrophic factor (GDNF) on modulating this sur-
vival. Exposure of primary enteric neurons to 20 mM glucose (hyperglycemia) for 24 hours resulted in a signifi-
cant increase in apoptosis compared with 5 mM glucose (normoglycemia). Exposure to 20 mM glucose resulted 
in decreased Akt phosphorylation and enhanced nuclear translocation of forkhead box O3a (FOXO3a). Treat-
ment of enteric neurons with GDNF ameliorated these changes. In streptozotocin-induced diabetic mice, there 
was evidence of myenteric neuronal apoptosis and reduced Akt phosphorylation. Diabetic mice had loss of 
NADPH diaphorase–stained myenteric neurons, delayed gastric emptying, and increased intestinal transit 
time. The pathophysiological effects of hyperglycemia (apoptosis, reduced Akt phosphorylation, loss of inhib-
itory neurons, motility changes) were reversed in diabetic glial fibrillary acidic protein–GDNF (GFAP-GDNF) 
Tg mice. In conclusion, we demonstrate that hyperglycemia induces neuronal loss through a reduction in Akt-
mediated survival signaling and that these effects are reversed by GDNF. GDNF may be a potential therapeutic 
target for the gastrointestinal motility disorders related to diabetes.
*OUSPEVDUJPO
Diabetes mellitus is a common disorder and has a worldwide 
prevalence of 6–7% (1, 2). Gastrointestinal dysfunction occurs 
in as many as 75% of diabetic patients (3, 4). Some of the com-
mon gastrointestinal problems seen in diabetes include delayed 
gastric emptying, diarrhea, constipation, and abdominal pain. 
The pathogenesis of intestinal motility dysfunction in diabetes 
remains unknown. The motility changes in the gastrointestinal 
tract in diabetes are considered to be an expression of autonomic 
neuropathy, with evidence for altered sympathetic function and 
cholinergic denervation of the gastrointestinal tract (5–7), vagal 
nerve dysfunction (8), sympathetic nerve damage (9), and damage 
to the enteric nerves (10–12).
The pathological lesions that occur in the enteric neurons in 
diabetes have been described. Loss of myenteric neurons has been 
reported in short-term diabetes (13, 14). A reduction in specific 
types of enteric neurons has been noted in several diabetic animal 
models, including streptozotocin-induced (STZ-induced) diabet-
ic rats (15, 16), STZ-induced diabetic mice (12), diabetic Chinese 
hamsters (6), and the OLETF rat model of type 2 diabetes (11). 
However, the mechanism underlying these changes in the enteric 
nervous system (ENS) in diabetes is not well defined. Neuronal 
apoptosis appears to contribute to the neurodegeneration seen in 
animal and cell culture models of diabetes (17). In the STZ model 
of diabetes, evidence of increased apoptosis in the dorsal root gan-
glion neurons, myenteric neurons, and nodose ganglia of diabetic 
rats has been demonstrated (18). Previous studies have shown that 
high glucose levels injure neuronal cell types, including Schwann 
cells, superior cervical ganglion neurons, and dorsal root ganglion 
neurons (19, 20). However, the effects of hyperglycemia on enteric 
neurons in culture have not been examined.
A reduction in neurotrophic factors can contribute to the chang-
es noted in diabetic peripheral neuropathy (21, 22). Glial cell line–
derived neurotrophic factor (GDNF) is an important neurotrophic 
factor for the ENS (23, 24). GDNF acts with the coreceptor glial 
cell line–derived neurotrophic factor receptor α (GFRα1) to acti-
vate the Ret tyrosine kinase receptor, stimulating both the MAPK 
and PI3K pathways (25). We and others have previously shown 
that the proliferation, maturation, migration, and survival of the 
enteric neurons are critically dependent on the activity of the Ret 
tyrosine kinase receptor that is expressed in the developing and 
mature enteric neurons (23, 25–27). GDNF-deficient mice also have 
severe intestinal aganglionosis (24). GDNF overexpression in glial 
fibrillary acidic protein–GDNF (GFAP-GDNF) Tg mice (Tg-DM 
mice) prevents a subpopulation of spinal and cranial motor neu-
rons from developmental programmed cell death and promotes 
complete survival of injured neonatal neurons (28). One of the 
major intracellular signaling pathways for neurotrophic factors 
is the PI3K signaling pathway. GDNF activates the PI3K pathway 
to promote enteric neuronal survival (26). Decreased PI3K signal-
ing has been implicated in vagal afferent neurons in STZ-induced 
diabetic rats (29). The effect of GDNF on diabetes-induced enteric 
neuronal damage is not known.
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In this study, we looked for evidence of damage to the enteric 
neurons in an experimental mouse model of diabetes as well as 
the effects of hyperglycemia on primary enteric neurons in cul-
ture and the possible mechanisms underlying this neuronal injury. 
The effects of the neurotrophic factor, GDNF, on hyperglycemia-
induced toxicity was evaluated in vitro using primary enteric neu-
rons in culture and in vivo using Tg mice overexpressing GDNF.
3FTVMUT
Hyperglycemia-induced apoptosis in enteric neurons is inhibited by GDNF. 
We examined the effects of hyperglycemia on primary enteric neu-
rons in culture. Enteric neurons from E14.5 rat guts were cultured 
for 24 hours in the presence of different concentrations of glucose 
(5, 10, or 20 mM) in serum-free/glucose-free media. These concen-
trations of glucose have been shown to evoke a significant depo-
larization in isolated enteric neurons (30). Cultured cells were then 
fixed, and the effect of glucose on apoptosis of enteric neurons was 
assessed by the Ret/Hoechst staining method (26). Hyperglycemia 
caused a dose-dependent increase in enteric neuronal apoptosis 
(Figure 1A). Hoechst is a nuclear stain that detects DNA fragmen-
tation and condensation in cells undergoing apoptosis (Figure 1B). 
Apoptosis was also assessed using the TUNEL method in conjunc-
tion with staining for neurons with Ret. There was a significant 
increase in apoptosis at the 20 mM glucose concentration com-
pared with 5 mM glucose (Figure 1C). We next determined wheth-
er the neurotrophic factor GDNF can ameliorate hyperglycemia-
induced apoptosis. In the presence of GDNF, the glucose-induced 
apoptosis was significantly reduced (Figure 1C). To assess the role 
of increased osmolarity in the hyperglycemic culture medium, 
mannitol was used as an osmolar control. The increase in enteric 
neuronal apoptosis (assessed by Ret/TUNEL staining) was second-
ary to hyperglycemia, but not secondary to hyperosmolarity, as the 
addition of 15 mM mannitol did not significantly increase apop-
tosis compared with 5 mM glucose (Figure 1C). Representative 
photographs of enteric neurons cultured in the presence of 5 mM 
and 20 mM glucose and assessed for apoptosis using the TUNEL 
method are shown (Figure 1D).
Hyperglycemia is associated with decreased Akt phosphorylation. We 
next examined the role of the PI3K pathway in the glucose-induced 
modulation of enteric neuronal apoptosis. GDNF is a known acti-
vator of the PI3K pathway in enteric neurons. Activation of the 
PI3K pathway results in phosphorylation of Akt (26). Enteric neu-
rons were cultured in medium containing 5 or 20 mM glucose in 
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24 hours and stained using a primary antibody to phospho-Akt 
(p-Akt). Peripherin was used as a neuronal marker. The percentage 
of neurons staining positive for p-Akt was significantly reduced 
in the presence of 20 mM glucose compared with 5 mM glucose. 
The addition of GDNF significantly increased the p-Akt–stained 
neurons as shown in Figure 2, A and B.
Hyperglycemia is associated with increased FOXO3a translocation. 
One of the main downstream targets of Akt is the forkhead 
family of transcription factors. Two members of the forkhead 
box O (FOXO) subfamily of forkhead transcription factors, 
FOXO1 and FOXO3a, critically regulate cellular differentiation 
(31) and neuronal survival (32). Enteric neurons were cultured 
in medium containing 5 or 20 mM glucose in the presence or 
absence of GDNF. Cells were cultured for 24 hours, fixed, and 
stained with primary antibody to FOXO3a and peripherin. The 
percentage of neurons with nuclear translocation of forkhead 
was significantly higher in 20 mM glucose compared with 5 mM 
glucose. Addition of GDNF to the medium resulted in a signifi-
cant reduction of forkhead nuclear translocation in the presence 
of 20 mM glucose (Figure 3).
Expression of constitutively active Akt rescues hyperglycemia-induced 
ENS apoptosis. To confirm the role of Akt in rescuing hyperglyce-
mia-induced apoptosis in enteric neurons, cells were transfected 
with a control plasmid-enhanced GFP (p-EGFP) vector or a con-
stitutively active Akt (CA-Akt) construct (33) and cultured in the 
presence of 5 mM or 20 mM glucose for 24 hours. Apoptosis was 
evaluated using the Ret/TUNEL method. Overexpression of Akt 
but not p-EGFP was able to rescue the enteric neurons from under-
going apoptosis in the presence of 20 mM glucose (Figure 4).
Diabetic mice exhibit enteric neuronal apoptosis and degeneration. In 
order to verify the changes induced by hyperglycemia on enteric 
neurons in culture and their reversal by GDNF in vivo, the STZ-
induced mouse model of diabetes was used. Diabetes was induced 
by intraperitoneal injection of STZ in WT (WT-DM) mice and 
in Tg-DM mice to assess the effects of overexpression of GDNF. 
Overexpression of GDNF in Tg-DM mice is driven by human 
GFAP promoter, which is known to be expressed in astrocytes in 
the central nervous system and some glial cells in the peripheral 
nervous system. WT control (WT-C) and GFAP-GDNF Tg control 
(Tg-C) mice were injected with vehicle.
WT-DM mice showed a significant decrease in body weight and 
a significant increase in the level of blood glucose when compared 
with WT-C mice 8 weeks after the induction of diabetes. The 
weight of Tg-C mice was lower than that of the WT-C mice. The 
Tg-DM mice showed a significant increase in serum glucose level 


























Downloaded on July 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/26295
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 116   Number 2   February 2006 
Electron microscopy provides the most convincing evidence of 
apoptotic cell death. A majority of the myenteric neurons from the 
proximal colon of diabetic mice showed evidence of neuronal apop-
tosis with clumping of the chromatin, condensation of the nucleus, 
mitochondrial ballooning, disruption of cristae, and disorganization 
of the neuropil. In contrast, neurons from the proximal colon of con-
trol mice displayed normal (diffuse) chromatin staining in the nucle-
us, normal mitochondria, and an organized neuropil (Figure 5).
GDNF overexpression prevents diabetic enteric neuronal apoptosis. The 
effect of GDNF on modulating the enteric neuronal apoptosis 
seen in diabetes was assessed in vivo using the Tg-DM mice. Apop-
tosis was assessed by activated caspase-3 staining. Overexpression 
of GDNF in the ilea of Tg-DM mice was confirmed by RT-PCR 
(Figure 6A) and immunostaining using an antibody specific for 
GDNF (Figure 6B). GFAP was used as a glial marker. These photo-
graphs show that GDNF expression was directed to the glial cells 
in the enteric ganglia. Frozen cross sections of ilea from mice were 
assessed for myenteric neuronal apoptosis using double-labeling 
immunohistochemistry for cleaved cas-
pase-3 and peripherin. Eight weeks after 
the induction of diabetes, the WT-DM 
mice had a significantly higher number 
of apoptotic neurons in the myenteric 
ganglia compared with WT-C mice (Fig-
ure 6, C and D). The percentage change 
in myenteric ganglia containing cleaved 
caspase-3+/peripherin+ neurons com-
pared with WT-C neurons is shown 
(Figure 6E). This increase in apoptosis is 
ameliorated in the Tg-DM mice.
Diabetes is associated with decreased 
expression of PI3K in enteric neurons. We 
next determined whether the increased 
apoptosis seen in the condition of diabetes was associated with 
a decrease in PI3K signaling. Frozen cross sections of WT-C and 
WT-DM mice ilea were assessed for myenteric neuronal p-Akt 
expression. As shown in Figure 7, A–C, 8 weeks after the induc-
tion of diabetes, the WT-DM mice had significantly fewer p-Akt–
positive neurons in the myenteric ganglia compared with WT-C 
mice. In addition, p-Akt was significantly reduced in myenteric 
neurons isolated from the ilea of diabetic mice compared with 
control mice as assessed by Western blot analysis using an anti-
body specific for p-Akt (Figure 7, D and E).
Diabetes is associated with loss of myenteric NADPH diaphorase–stained 
neurons, and this is rescued by GDNF. Having demonstrated that dia-
betes is associated with enhanced apoptosis in enteric neurons, we 
assessed the subtype of neurons affected in diabetes. Using whole-
mount analysis of mouse ilea, we assessed the neuronal NO syn-
thase–containing (nNOS-containing) neurons (NADPH diapho-
rase stained), cholinergic neurons (choline acetyltransferase [ChAT] 
stained), and the total number of neurons (peripherin stained and 
PGP9.5 stained). The number of NADPH diaphorase–stained neu-
rons, large and small fibers, was significantly decreased in WT-DM 
mice after 8 weeks of diabetes compared with WT-C mice (Figure 8, 
A–C). In the Tg-DM mice, the expression of GDNF ameliorated the 
loss of NADPH diaphorase–stained neurons, large and small fibers. 
No change in the number of acetylcholine esterase–stained excit-
atory neurons, large fibers or small fibers, was noted among all 4 
groups of mice (Figure 8, D–F). This was confirmed by staining for 
cholinergic neurons using an antibody specific for ChAT (Figure 9, 
A and C). Total number of neurons was assessed by peripherin stain-
ing. The number of peripherin-positive neurons was significantly 
decreased in WT-DM mice compared with WT-C mice. In Tg-DM 
mice, the expression of GDNF ameliorated the loss of peripherin-
stained neurons (Figure 8, G and H). Total number of neurons was 
















Characteristics of control and STZ-induced diabetic mice
 Blood glucose  Blood glucose  Weight on the  Weight 8 weeks  
 on the day of  8 weeks after  day of injection  after injection  
 injection (mg/dl) injection (mg/dl) (g) (g)
WT-C 158.5 ± 10.5 141.8 ± 0.8 41.25 ± 0.5 46.3 ± 2.1
WT-DM 152.6 ± 6.2 465.5 ± 8.5C 43 ± 1.5 34 ± 2.3A
Tg-C 145.5 ± 23.5 149 ± 0 32 ± 1.5B 35.3 ± 1.8
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was significantly decreased in WT-DM mice compared with WT-C 
mice. In Tg-DM mice, the expression of GDNF ameliorated the loss 
of PGP9.5 (Figure 9, A and B).
Diabetic mice have delayed gastric emptying and increased intestinal tran-
sit, and these changes are reversed by GDNF. Gastric emptying and intes-
tinal transit were assessed in WT-C, WT-DM, Tg-C, and Tg-DM 
mice as described in Methods. Figure 10A shows a representative 
photograph of the intestinal transit of methylene blue. As shown 
in Figure 10B, there was a significant delay in gastric emptying in 
WT-DM mice (8 weeks of diabetes) compared with WT-C mice. This 
delay in gastric emptying was significantly improved in Tg-DM 
mice. The rate of intestinal transit 30 minutes after the admin-
istration of methylene blue was significantly higher in WT-DM 
compared with WT-C mice. The presence of the GFAP-GDNF 
transgene in the diabetic mice (Tg-DM) reduced the rate of intes-
tinal transit (Figure 10C).
Diabetes is associated with impaired colonic relaxation in response to inhib-
itory neuronal stimulation, and these changes are reversed in the Tg-DM 
mice. The effect of electric field–induced stimulation (EFS) of 
inhibitory neurons was assessed using isometric muscle tension 
recording. The effect of inhibitory neurons was confirmed by 
performing colonic longitudinal muscle strip stimulation in the 
presence of atropine and guanethidine. Percentage relaxation was 
calculated by determining the difference between the maximal 
baseline force and the minimum force following electrical stimu-
lation and expressing this as a percentage of the force generated at 
baseline. Transmural EFS (100 V, 20 Hz, 5 milliseconds, 60 
seconds), which evoked relaxation of the proximal colon, 
was significantly impaired in diabetic mice compared with 
controls. The induction of diabetes in the Tg-DM mice did 
not result in impairment of colonic relaxation (Figure 11A). 
Representative tracing of an EFS-induced relaxation record-
ing is shown in Figure 11B. These data support ameliora-
tion of inhibitory neuronal loss in diabetes in the presence 
of GDNF overexpression. No change in the baseline ampli-
tude of colonic contractions was noted between WT-C and 
WT-DM mice. Measurement of rebound contraction after 
relaxation with EFS was no different in all 4 mouse groups 
(data not shown), indicating no significant differences in 
the excitatory neuronal responses.
%JTDVTTJPO
The etiology of the gastrointestinal complications of diabetes 
is multifactorial. There is evidence of damage to the ENS in 
animal models of diabetes (13, 14) and in human diabetic 
patients (10). In the current study, we examined the role of 
hyperglycemia in inducing damage to the enteric neurons 
and the underlying mechanism of this damage. Using an in 
vitro culture system of enteric neurons as well as an in vivo 
STZ-induced diabetic model, we demonstrated that hyper-
glycemia is associated with enteric neuronal apoptosis. Fur-
ther, we demonstrated alteration in the PI3K pathway and a 
subsequent loss of inhibitory myenteric neurons in neuronal 
cell culture as well as in diabetic mice. Importantly, we dem-
onstrated, for what we believe is the first time, that the neu-
rotrophic factor GDNF reverses hyperglycemia-induced 
neuronal apoptosis and loss of nNOS-containing neurons 
and also improves gastrointestinal motility in diabetic mice.
Neuronal apoptosis has been shown to contribute to the 
complications of diabetic retinopathy. Increased retinal 
neuronal apoptosis leading to neurodegeneration has been demon-
strated in a STZ-induced rat model of diabetes (34). Diabetes-relat-
ed programmed cell death has been demonstrated in the hippocam-
pus of type 1 BioBreeding/Worcester (BB/W) rats (35). Apoptotic 
death in diabetic neuropathy has been related to hyperglycemia and 
oxidative stress (20, 36, 37). In the human neuroblastoma cell line 
SH-SY5Y, exposure to 20 mM glucose causes an increase in ROS, 
mitochondrial membrane depolarization, and cleavage of caspases 
(20). High glucose levels may result in depolarization of neurons 
and increased intracellular calcium (38). This may be a mechanism 
of glucotoxicity in enteric neurons, as they are known to be glucose 
responsive and to express an ATP-sensitive K+-channel (30).
Alterations in insulin signaling and tyrosine kinase activity as well 
as reduction in neurotrophic factor support have been implicated 
in the pathophysiology of diabetic complications. In our study, we 
have demonstrated that hyperglycemia decreased p-Akt both in cell 
culture and in a diabetic animal model. These changes were reversed 
by the neurotrophic factor GDNF. Impaired retrograde transport of 
neurotrophic factors has been demonstrated in somatic and auto-
nomic nerves in experimental diabetes. In STZ-induced diabetic 
rats, a decrease in the activation of the PI3K pathway was associ-
ated with the impairment of retrograde nerve growth factor (NGF) 
transport in the vagus nerve (29). GDNF alleviated the glucose-
induced sensory deficits in a subset of sensory neurons called the 
IB-4–positive nonpeptidergic, unmyelinated primary afferent neu-
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in hippocampal neurons was shown in a type 1 diabetic model (40). 
The antiapoptotic effect of insulin is mediated through alteration of 
the PI3K pathway, leading to activation of NF-κB (41). Recently, the 
role of statins in the therapy of diabetic neuropathy involving the 
sciatic nerve was shown. Rouvastatin, an HMG CoA reductase inhib-
itor, has a favorable effect on diabetic neuropathy that is indepen-
dent of its cholesterol-lowering effect. It restored nNOS expression 
in Schwann cells under high glucose conditions through activation 
of the PI3K pathway, resulting in restoration of the microcircula-
tion of the sciatic nerve (42). IGF-1 activation of the PI3K path-
way results in protection from glucose-mediated apoptosis in this 
model, and this protection is lost in the presence of the PI3K inhibi-
tor LY294002 (43, 44). Growth factors such as NGF also block this 
induction of ROS and stabilize the mitochondrial membrane poten-
tial (20). Therapy with nerve growth factor improves unmyelinated 
fiber morphology and function in diabetic mice (45) and improves 
sensation and sensory function in patients with diabetic neuropathy 
(46). In a subpopulation of nonpeptidergic unmyelinated sensory 
neurons, GDNF but not NGF administration can selectively reverse 
deficits caused by diabetes (39). Our future studies will focus on the 
signal transduction differences between NGF and GDNF in amelio-
rating diabetic neuropathy. Our findings demonstrate a reduction 
in PI3K signaling in the enteric neurons in diabetes and the ability 
of GDNF overexpression to ameliorate these findings. Further stud-
ies will need to be done in both diabetic animal and human tissue 
samples to assess the levels of GDNF in enteric neurons.
Chronic hyperglycemia has been shown to impair PI3K signal-
ing in skeletal muscle (29, 47). Amelioration of hyperglycemia 
without alteration of insulin levels normalizes the PI3K activity in 
skeletal muscle (29). Proper serum glucose control has been shown 
to prevent or ameliorate the nerve damage responsible for diabetic 
retinopathy and nephropathy (48, 49). In the current study, we 
report the effects of hyperglycemia on a primary embryonic enteric 
neuronal culture system. Hyperglycemia was shown to decrease 
PI3K signaling, although the exact mechanism is not known and 
needs to be further investigated. We also found a reduction in PI3K 
signaling in adult myenteric neurons. Our findings in the enteric 
neurons can be extended to adult neurons. We demonstrated the 
role of hyperglycemia-induced changes in the PI3K pathway and 
subsequent apoptosis and loss of enteric neurons. GDNF has also 
been shown to activate the MAPK pathway (25). We have previously 
reported that GDNF-mediated enteric neuronal survival is through 
the PI3K pathway and not the MAPK pathway (26). Further studies 
will need to be performed to evaluate the role of the MAPK pathway 
in hyperglycemia-induced enteric neuronal damage.
The molecular mechanism of hyperglycemia’s alteration of PI3K 
activity is not known. Possible mechanisms include phosphoinosit-
ide-dependent protein kinase-1 (PDK-1) and PDK-2 inhibition, acti-
vation of PI3-phosphatase that leads to a decrease in the cellular 
contents of lipid products by PI3K, a defect in intracellular PI3K 
translocation, and activation of a phosphatase that may modify 
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in a reduction in the level of IGF-1 receptor (50). Similar mecha-
nisms may be associated with the reduced PI3K signaling noted in 
our study. Another mechanism for reduced PI3K signaling in the 
diabetic animals may be secondary to the weight loss noted in these 
animals. Several factors contribute to the weight loss in diabetic ani-
mals, including glucosuria and diarrhea. In the diabetic Tg animals, 
the absence of weight loss may be due to the correction of the gas-
trointestinal motility disturbances that are noted in these animals.
We have demonstrated that overexpression of GDNF in glial 
cells adjacent to the enteric neurons results in an increase in NO-
containing inhibitory neurons. As previously shown, GDNF is effi-
ciently secreted from astrocytes and acts in a paracrine fashion to 
promote complete and long-lasting survival of injured neonatal 
facial motor neurons (28). We believe that, similar to the effects of 
GDNF in the central nervous system, where the astrocytes secrete 
GDNF to affect motor neurons, the GDNF in the glial cells is 
secreted adjacent to enteric neurons. The NADPH diaphorase–
containing neurons could be inhibitory neurons, interneuronal 
neurons, or primary afferent neurons. Loss of nNOS-containing 
neurons in diabetes can result in delayed gastric emptying due to 
loss of neurons in the pylorus and accelerated intestinal transit 
due to loss of inhibition influence of these neurons in the small 
and large intestines. The defective gastric accommodation is due 
to impaired NOS expression in the gastric myenteric plexus in 
the spontaneously diabetic BB/W rat model (51). Delayed gastric 
emptying in diabetes is secondary to loss of neuronal NOS expres-
sion and function (12). Cellek et al. demonstrated loss of nitrergic 
function and neurons in the penises and pylori of STZ-treated 
diabetic rats, and only the loss of nNOS content and function was 
reversible by insulin, not the neuronal loss (52, 53). Our results 
show loss of nNOS-containing neurons in the intestine, which 
can contribute to the increased intestinal transit seen in diabetes. 
GDNF can prevent the enteric neuronal loss and ameliorate the 
increased intestinal transit in diabetes. Thus, the activation of the 
PI3K pathway can prevent the loss of nNOS-containing neurons 
seen in diabetes. We did not see a change in the cholinergic neu-
rons in diabetes. This may reflect the duration of diabetes that we 
examined in our experiments.
Insulin improves the delayed gastric emptying seen in the STZ 
model of diabetes at 8 weeks (12). We now demonstrate that 
GDNF can perform a similar function by increasing the number of 
NADPH diaphorase–containing neurons. Other gastrointestinal 
problems in diabetes include diabetic diarrhea and constipation. 
The reduction in intestinal NADPH diaphorase–containing neu-
rons and subsequent increase in intestinal transit can contribute 
to this diarrhea. NO-related mechanisms regulate human small 
intestinal motility (54). Symptoms of diabetic gastroparesis and 
diabetic diarrhea can worsen in patients with poor glucose con-
trol. Thus, both acute and chronic hyperglycemia can affect gas-
trointestinal motility, and we believe that alteration in the PI3K 
pathway can contribute to this. Loss of nNOS-containing enteric 
neurons has been noted in conditions of congenital pyloric ste-
nosis, achalasia, and Hirschsprung disease (25). The regulation of 
the PI3K pathway may be altered in these conditions, and this area 
needs to be further investigated.
Our finding of reduced nitrergic neurons in diabetic neuropathy 
has potential therapeutic implications. Currently, the major drugs 
used for treating patients with diabetic gastropathy include dom-
peridone (dopaminergic antagonist), metachlopramide (55), and 
erythromycin. Knowledge of the specific molecular mechanisms of 
hyperglycemia-induced enteric neuronal damage may have signifi-
cant implications in the design and testing of therapeutic regimens 
for diabetic enteric neuropathy. Our results demonstrate the role of 
the PI3K pathway on hyperglycemia-induced neuronal loss. GDNF 
reverses the morphological and functional effects of hyperglycemia 
on enteric neuronal survival and may be a potential therapeutic tar-
get for gastrointestinal motility disorders in diabetes.
.FUIPET
Materials. The components for primary culture were bovine insulin, bovine 
serum albumin fraction V, fetuin selenium, putrescine, and progesterone; 
all were obtained from Sigma-Aldrich. Also used were dispase and collage-
nase (CLS4; Worthington Biochemical Corp.), rat transferrin (ChromPure; 
Jackson ImmunoResearch Laboratories Inc.), 8-well culture slides and 6-well 
plates coated with poly-D-lysine and laminin (BD Biosciences), and prefilter 
and columns for magnetic separation (Miltenyi Biotec).
We also used the following: antibodies to low-affinity NGF receptor 
(p75NTR, clone192; Chemicon International, MAB365), c-Ret (Immuno-
Biological Laboratories Inc.), peripherin for immunocytochemistry (Chemi-
con International, MAB1527), Akt (Cell Signaling Technology), peripherin 
for whole mount (Chemicon International, AB1530), p-Akt for Western 
blotting (Cell Signaling Technology), p-Akt for immunocytochemistry 
(Promega), rabbit IgG, HRP–linked (Cell Signaling Technology), FOXO3a 
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GDNF and GFAP (Santa Cruz Biotechnology Inc.), goat anti-mouse, FITC-
labeled, donkey anti-rabbit biotin, donkey anti-mouse biotin, and peroxi-
dase-conjugated streptavidin (Jackson ImmunoResearch Laboratories Inc.).
Other reagents were as follows: tyramide signal amplification kit 
(TSA-FITC or TSA-Cy3, NEN Life Science Products), Hoechst 33258 
(Sigma-Aldrich), TUNEL Kit (Roche Diagnostics Corp.), STZ (Sigma-
Aldrich), methylene blue (Mayne Pharma), dextrose (Sigma-Aldrich), 
mannitol (Fisher Diagnostics), PicoPure RNA Isolation Kit (Arcturus), 
Omniscript Reverse Transcription Kit (QIAGEN) and random hexam-
ers (Invitrogen Corp.), Taq DNA polymerase (Promega), p-EGFP vector 
(BD Biosciences), CA-Akt construct (kind gift from Phil Stahl, Wash-
ington University, St. Louis, Missouri, USA), and lipofectamine 2000 
(Invitrogen Corp.). GDNF was produced as previously described (56) 
and stored at –70°C in aliquots. Fluorescent photomicrographs were 
obtained on a Leica microscope. Certain images were also taken using a 
Zeiss LSM 510 confocal microscope. Electron microscopic images were 
taken using a Hitachi H-7500 transmission electron microscope.
Primary culture and magnetic bead immunoselection of p75-expressing cells. 
Stomachs and small and large bowels from E14.5 Sprague-Dawley rat 
embryos (10–12 embryos) were dissociated with collagenase and dispase 
to prepare a single-cell suspension, as previously described (23, 57). In 
brief, the dissociated cells were incubated with a monoclonal antibody to 
low-affinity NGF receptor (p75NTR, 10 μg/ml), washed, and labeled with 
goat anti-mouse IgG microbeads (50-nm diameter; Miltenyi Biotec). Cells 
expressing p75 bound to the microbeads were retained in the presence of a 
magnetic field (0.6 Tesla) while the remainder of the cells passed through. 
To collect the retained cells, the column was removed from the magnetic 
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of immunoselected cells, calculated from several consecutive experiments, 
averaged 0.8–1.0 × 106 cells (approximately 10% of the total cells). Follow-
ing immunoselection, cells were resuspended in modified N2 medium, and 
12,500 trypan blue–excluding cells in 125 μl of N2 medium were plated 
into a single well of an 8-well slide coated with poly-D-lysine and laminin. 
An additional 125 μl of medium was added to each well with the desired 
factors. Cells were grown in the medium in a humidified tissue culture 
incubator containing 5% CO2 at 37°C. Unless otherwise stated, cells were 
grown in the presence of GDNF (100 ng/ml). As described by other inves-
tigators (58), our immunoselection method yielded a population of 80% 
Ret-positive cells after 24 hours of culture. The p75-negative fraction had 
less than 10% Ret-positive cells.
Ret/Hoechst and Ret/TUNEL double labeling. Enteric neurons were treated 
with different glucose concentrations (5, 10, or 20 mM glucose or 5 mM glu-
cose plus 15 mM mannitol) in the presence or absence of GDNF (100 ng/ml) 
in serum-free/glucose-free medium and maintained in culture for 24 hours. 
Neurons were fixed with 4% paraformaldehyde (pH 7.35, 30 minutes, 25°C), 
and permeabilized with 0.1% Triton-X 100, 0.1% sodium citrate in PBS (pH 
7.4; 2 minutes on ice). Staining for c-Ret was performed using a rabbit 
anti c-Ret primary antibody (1:100) in conjunction with a tyramide signal 
amplification kit (1:100, TSA-Cy3) as described previously (26). To visual-
ize Hoechst-positive cells, slides were washed in PBS and then incubated 
with Hoechst stain (2.5 μg/ml) for 3 minutes at room temperature. At least 
800 Ret-expressing neurons from 4 independent experiments 
were scored in a blinded fashion to determine the percentage of 
Hoechst+/Ret+ cells. To visualize TUNEL-positive cells, slides were 
washed in PBS and then incubated with FITC-labeled dUTP in 
the presence of terminal deoxynucleotidyl transferase (TdT) for 1 
hour at 37°C. We scored 400 RET-expressing neurons in a blinded 
fashion to determine the percentage of TUNEL+/Ret+ cells.
Analysis of Akt phosphorylation. p75 immunoselected enteric neu-
rons were cultured in N2 medium containing 5 or 20 mM glucose 
and in the presence or absence of GDNF (100 ng/ml) for 24 hours. 
Cultures were fixed in 4% paraformaldehyde (30 minutes, 25°C) 
and then permeabilized with 0.1% Triton-X 100 and 0.1% sodium 
citrate in PBS (2 minutes on ice). p-Akt–positive cells were visual-
ized using an antibody specific for the phosphorylated form of Akt 
(p-Akt473; 1:100 dilution, 4°C, overnight), followed by secondary 
antibodies and the TSA-Cy3 detection method as described above 
for Ret immunocytochemistry. Peripherin was used as a counter-
stain to identify neurons by using a TSA-FITC detection method. 
At least 800 peripherin-expressing neurons from 4 independent 
experiments were scored in a blinded fashion, and the percentage 
of p-Akt–positive cells was determined using Scion Image beta 
4.0.2 software (Scion Corp.) to quantitate fluorescence.
Forkhead translocation. Immunoselected enteric neurons were 
cultured in N2 medium containing 5 or 20 mM glucose and in the 
presence or absence of GDNF (100 ng/ml) for 24 hours. Cells were 
then fixed (4% paraformaldehyde, 30 minutes, 25°C) and permea-
bilized with 0.1% Triton-X 100 and 0.1% sodium citrate in PBS 
(2 minutes on ice). Immunocytochemistry was first performed 
with a primary antibody to FOXO3a (1:100) and a TSA-Cy3 kit as 
described above. Cells were then stained with an anti-peripherin 
antibody and a TSA-FITC kit. At least 800 peripherin-expressing 
neurons from 4 independent experiments were scored in a blind-
ed fashion, and the percentage of peripherin-expressing neurons 
with forkhead localized in the nucleus was determined using 
Scion Corp. imaging software to quantitate fluorescence.
CA-Akt transfection method. The role of Akt in rescuing the hyper-
glycemia-induced apoptosis in enteric neurons was confirmed by 
transfecting the cells with CA-Akt. CA-Akt lacks amino acid 4-129 and has 
a 14–amino acid src myristoylation signal on the amino terminus of Akt 
that targets Akt to the membrane (33). Enteric neurons were cultured in 
the presence of GDNF (100 ng/ml) for 24 hours. Medium was replaced 
with either 5 or 20 mM glucose, and the cells were transfected with control 
p-EGFP construct (p-EGFP; 0.473 μg/μl) or a CA-Akt construct (CA-Akt; 
3.962 μg/μl) with p-EGFP for 24 hours, using Lipofectamine 2000 per 
manufacturer’s protocol. Cells were fixed and assessed for apoptosis by 
the Ret/TUNEL double-labeling method as described above.
STZ-induced diabetes mellitus in mouse model. All animal studies were approved by 
the Emory University Institutional Review Board. Tg-DM mice were generated 
by cloning the full-length mouse GDNF cDNA into the pGFAP–human growth 
hormone expression cassette containing a 2.2-kb fragment of the human GFAP 
promoter. Generation and characterization of these mice is described elsewhere 
(28). Integration of the transgene into the mouse genome was determined by 
PCR on genomic DNA extracted from mouse tail using forward (5′-AGCT-
CACTGCAGCCTCACCTACT-3′) and reverse (5′-CAGGCATATTGGAGT-
CACTGG-3′) primers in conditions described previously (28).
These mice overexpressed GDNF in both the central nervous system 
and the peripheral nervous system. The Tg-DM mice at birth exhibited 
an obvious tremor. The tremor gradually reduced with maturation and 
was undetectable after 2–3 weeks of age. The tremor may be a reflection of 
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pearance correlates with gradual loss of multiple innervation of skeletal 
muscles (28). These mice weighed 20% less than age-matched littermate 
controls. Despite this weight loss, eye opening, fur growth, weaning, and 
reproduction capacity were comparable to control. These mice were fed 
ad libitum. Eight-week-old male Tg-C and WT-C littermates were injected 
intraperitoneally with either STZ in 0.05 M citrate buffer, pH 7.4 (200 mg/kg), 
or vehicle alone. Blood glucose and weight of the mice were measured prior 
to injection as well as 48 hours and 8 weeks after injection of STZ, and the 
averages are shown in Table 1 (48-hour measurement not shown).
Electron microscopy. Proximal colon tissue was obtained from WT-C and 
WT-DM mice and fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, 
pH 7.2, overnight at 4°C, followed by 3 washes with the same buffer. Sam-
ples were then treated with 1% osmium tetroxide in 0.1 M cacodylate buffer 
for 1 hour at room temperature. After fixation with osmium, samples were 
dehydrated through an ascending ethanol series and embedded with epoxy 
resin. Ultrathin sections were stained with uranyl acetate and lead citrate and 
examined with a Hitachi H-7500 transmission electron microscope.
RT-PCR. Total RNA was isolated from whole-ileum tissue of WT-C and Tg-DM 
mice using the PicoPure RNA Isolation Kit reagents (Arcturus), and 1 μg 
RNA was reverse transcribed into first-strand cDNA using Omniscript reverse 
transcriptase (QIAGEN) and random hexamers (Invitrogen Corp.). Transgene 
mRNA was detected by RT-PCR using a set of primers that detect only the 
mRNA transcribed from the Tg construct (28, 59). As an internal control, we 
used primers specific to the GAPDH housekeeping gene. For semiquantitative 
PCR, 25 μl reactions were set up, comprising ×1 Taq DNA polymerase buffer, 
1.5 mM MgCl2, 200 μM dNTP mix, 0.4 μM each of the GDNF or GAPDH 
oligonucleotide primers, 1.25 U Taq DNA polymerase, and 1 μl first-strand 
cDNA. The samples were heated for 3 minutes at 95°C and subjected to 30 
cycles of PCR amplification, each cycle consisting of 30 seconds at 95°C, 
 30 seconds at 60°C, and 45 seconds at 72°C. A 
final extension for 7 minutes at 72°C was per-
formed before cooling to 4°C. The reaction was 
analyzed on a 2% ethidium bromide–stained 
agarose gel, and the amplified products were 
visualized by UV transillumination.
Assessment of apoptosis and Akt phosphorylation 
in mouse ilea. Ilea immediately adjacent to the 
cecum were obtained from WT-C, WT-DM, 
Tg-C, and Tg-DM mice and fresh frozen in 
OCT on dry ice. Frozen sections of 6 μm were 
obtained and fixed in 4% paraformaldehyde 
(pH 7.35, 30 minutes, 25°C), followed by per-
meabilization with 0.1% Triton-X 100 and 
0.1% sodium citrate in PBS (pH 7.4, 2 minutes 
on ice). Staining for cleaved caspase-3 was 
performed using a rabbit anti-cleaved cas-
pase-3 (Asp175) polyclonal antibody (1:100) 
in conjunction with a tyramide signal ampli-
fication kit (1:100, TSA-Cy3) as described 
previously (26). Sections were rinsed with 
PBS and blocked with 2% BSA in PBS (1 hour, 
room temperature) and then double labeled 
for peripherin using a mouse anti-periph-
erin antibody (1:100) in conjunction with a 
goat anti-mouse FITC-linked antibody. Fifty 
peripherin-positive ganglia per section were 
scored in a blinded fashion to determine the 
percentage of caspase+/peripherin+ ganglia. At 
least 6 sections were scored for each condition 
in 3 separate mice.
For p-Akt/peripherin double labeling, a similar staining protocol was used, 
and the primary antibody rabbit anti-pS473 Akt antibody (1:100) was used. 
Fifty peripherin-positive ganglia per section were scored in a blinded fashion 
to determine the percentage of p-Akt+/peripherin+ ganglia. At least 6 sections 
were scored for each condition in 3 separate mice.
GFAP/GDNF double labeling. GDNF overexpression in Tg mice was further 
confirmed by immunohistochemistry. Sections were fixed as described 
above and blocked with 5% BSA (in PBS), and WT-C and Tg-C mouse sec-
tions were stained for GDNF using a rabbit anti-GDNF (1:50 in 1% BSA) 
and TSA-Cy3 kit as described above. Sections were then counterstained 
with a goat anti-GFAP antibody (1:50) in conjunction with a donkey anti-
goat FITC lined antibody. GFAP was used as a glial cell marker. At least 5 
sections were scored for WT-C and Tg-C mice.
Isolation (and protein extraction) of myenteric plexus from ilea of control and dia-
betic mice. WT-C and WT-DM mice ilea were collected in chilled L-15 medi-
um and were cut into 1.0–1.5–cm segments. Strips of longitudinal muscle 
with attached myenteric ganglia were dissected under a dissecting micro-
scope and collected in L-15 medium on ice. The tissue was then transferred 
to a tube containing 2 ml of collagenase, type II (1 mg/ml) in HBSS and 
incubated for 90 minutes. In step 1, the tube was vortexed for 20 seconds. 
The partially digested tissue was allowed to settle and supernatant was col-
lected and then screened under a dissecting microscope for myenteric gan-
glia or cells and spun down at 1,150 g for 10 minutes at 4°C. In step 2, the 
cells were suspended in about 1 ml of L-15 medium and kept on ice. Fresh 
collagenase solution (1 ml) was added to the remaining partially digested 
pieces and incubated at 37°C for 30 minutes. This process was repeated 2–3 
times. Steps 1 and 2 were repeated after every incubation, and cells were col-
lected in the same tube. This process resulted in most of the myenteric plex-
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were spun down, the supernatant removed completely, and the cells were 
washed in L-15 medium followed by ice-cold PBS. Lysis buffer (50–80 μl 
containing 1 mM PMSF and 100 nM okadaic acid) was added to the pellet, 
kept on ice for 5 minutes, sonicated 4 times for 5 seconds each on ice, and 
microcentrifuged for 10 minutes at maximum speed (15,700 g). Then the 
supernatant cell lysate was transferred to a new Eppendorf tube and stored 
at –80°C. Protein was measured by the Lowry method.
Western blotting. For each lane, 6 μg of protein was loaded onto a 12% 
Tris-HCl gel. Western blotting for p-Akt was performed as described (62). A 
semiquantitative measurement of the band intensity was performed using 
the Scion imaging computer software program and expressed as pixel 
intensity per unit area.
Whole mount. Small bowel was dissected from mice, and the mesentery 
was removed. Three pieces of ileum (4 cm; labeled 1, 2, and 3, 1 being the 
closest to the cecum) were cut along the mesentery and pinned down 
flat onto a glass dish with silicone coating. The intestines were fixed 
in 4% paraformaldehyde (1 hour, room temperature). The myenteric 
plexus and the longitudinal muscle layer were separated from the rest of 
the intestine and used for staining. Ileum piece 1 was used for periph-
erin staining, 2 for NADPH diaphorase, and 3 for acetylcholine esterase 
staining. For NADPH diaphorase staining, the fixed tissue was washed 
in PBS and incubated in diaphorase solution (β-NADPH diaphorase, 
1 mg/ml; nitroblue tetrazolium, 0.1 mg/ml; and 0.3% Triton-X 100 
in PBS) for 1 hour at 37ºC. This was followed by washing in PBS and 
mounting of the tissue on a glass slide. For acetylcholine esterase stain-
ing, the fixed tissue was washed in PBS and incubated in fresh copper 
buffer solution (100 ml dH2O, 7.2 mg ethopropazine, 115.6 mg acetyl-
thiocholine iodide, 75.0 mg glycine, 50.0 mg copper sulfate pentahy-
drate, 885.0 mg sodium acetate trihydrate; pH to 5.6 with glacial acetic 
acid) for 2 hours. This was followed by a wash in dH2O, 1 minute in 
1.25% sodium sulfide nonahydrate solution, a second wash in dH2O, 
then mounting of the tissue on a glass slide. Peripherin staining was 
performed on the fixed intestinal tissue using a rabbit anti-peripherin 
polyclonal antibody (1:500) in conjunction with a tyramide signal ampli-
fication kit (1:100, TSA-Cy3) as described previously (63).
Myenteric fiber count was performed on both NADPH diaphorase and 
acetylcholine esterase–stained intestines by counting fibers crossing a 
0.1 mm2 grid with 10 horizontal and 10 vertical lines. Twenty randomly 
selected fields per mouse were evaluated from 4 animals of each geno-
type. The neurons were counted within the 0.1 mm2 grid. Total number 
of neurons was expressed as peripherin-positive neurons per grid. Data 
were analyzed using the InStat software (version 2.04; GraphPad) in con-
junction with ANOVA.
Immunohistochemistry for ChAT and PGP9.5. Frozen sections (6 μm) were 
obtained from WT-C, WT-DM, Tg-C, and Tg-DM mice and fixed and 
permeabilized as described above. For PGP9.5 staining, the sections were 
blocked in 10% normal donkey serum and incubated with primary anti-
body (PGP9.5, 1:2000, in 1% normal donkey serum) for 24 hours followed 
by detection with the TSA-Cy3 secondary detection system as described 
above. For ChAT staining, the sections were blocked with 5% BSA and incu-
bated overnight in 1:100 primary antibody in 1% BSA. Secondary detec-
tion was performed by incubation with an Alexa Fluor 488 rabbit anti-goat 
antibody (1:500) dilution. Three randomly selected fields per section were 
evaluated in a blinded fashion from at least 5 sections per mouse.
Measurement of intestinal transit and gastric emptying. WT-C, WT-DM, Tg-C, 
and Tg-DM mice received an injection of 0.1 ml of methylene blue–labeled 
10% dextrose solution, using oral gavage. At the indicated time (5 or 30 
minutes), mice were sacrificed. The stomach was clamped with a string 
above the lower esophageal sphincter and a string beneath the pylorus 
to prevent leakage of methylene blue. The intestinal transit was mea-
sured from the pylorus to the most distal point of migration of methy-
lene blue. The total length of the small intestine was measured, and the 
transit time was expressed as percentage of total intestinal length as well 
as cm migration of methylene blue (12, 64). The stomach was cut just 
beneath the strings and frozen at –70°C until measurement of gastric 
emptying. Gastric emptying of liquids was determined as described previ-
ously (12, 64). Excised stomachs were minced and homogenized for 30 
seconds in 15 ml of 0.1 N sodium hydroxide. An additional 5 ml of 0.1 N 
sodium hydroxide was added and kept at room temperature for 1 hour. 
Supernatant (5 ml) was then centrifuged at 1,250 g for 20 minutes at 
4°C. Absorbance of the samples was read at a wavelength of 570 nm. 
The stomach and its contents obtained from mice sacrificed at the 
5-minute time point (after orogastric administration of methylene blue) 
served as a reference stomach measurement. The percentage of gastric 
emptying was calculated by the following formula: [(A570 reference 
— A570 sample)/A570 reference] × 100. Gastric emptying of methylene 
blue was expressed as the percentage of gastric emptying of the sample 
compared with the reference stomach. Retro-orbital blood samples were 
obtained from mice before and 30 minutes after gavage with methylene 
blue and the serum assessed for methylene blue. No methylene blue was 
detected in the serum of mice fed with methylene blue. We also correlated 
the gastric emptying assessed by methylene blue with that of a colloidal 
suspension (charcoal) and found similar results.
Isometric muscle recording. Longitudinal muscle strips were obtained from 
the proximal colons of WT-C, WT-DM, Tg-C, and Tg-DM mice. The strips 
were mounted between 2 hooks and placed between 2 platinum electrodes 
in 50 ml chambers containing Krebs buffer (NaCl, 118 mM; KCl, 4.7 mM; 
KH2PO4, 1.2 mM; MgCl2, 1.2 mM; NaHCO3, 23 mM; EDTA, 0.3 mM; 
glucose, 10 mM; and CaCl2, 2.5 mM; pH 7.4) at 37°C and continuously 
gassed with 95% O2 and 5% CO2. Tension was monitored with an isomet-
ric force transducer and recorded using the PowerLab recording software 
(version 5.2.1; ADInstruments). The intestinal strips were equilibrated for 
1 hour with 4.9 mN of tension applied. The colonic relaxation measured 
in response to transmural stimulation was recorded by EFS (100 V, 20 Hz, 
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(1 μM) and guanethidine (1 μM). For quantitative determination of relax-
ation, we used intestinal strips from any given treatment condition and 
used the first relaxation under that condition. The NO dependence of the 
relaxation was confirmed by incubation with L-NAME prior to EFS. This 
relaxation was completely abolished by tetrodotoxin (10–7 M) which indi-
cated mediation by a neuronal pathway. L-NAME (10–4 M) significantly 
reduced NANC by 70%, suggesting that muscle relaxation was primarily 
mediated by NO production from the myenteric plexus.
Statistics. Results are expressed as mean ± SEM. The data for all experiments 
was compared using a 2-tailed Student’s t test, assuming unequal variance. 
P values of less than 0.05 were considered to be statistically significant.
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